logo
Plus   Neg
Share
Email

Novartis To Initiate Proof Of Concept Study With Cosentyx - Quick Facts

Novartis (NVS) announced the plan to initiate ARROW, a head-to-head proof of concept study to assess the mechanistic superiority of the direct inhibition of IL-17A with Cosentyx (secukinumab) over the inhibition of IL-23 with Tremfya (guselkumab) in patients with psoriatic plaques resistant to treatment with Stelara. Study results are expected in 2019.

Cosentyx is the first fully-human biologic that specifically inhibits interleukin-17A (IL-17A), a cornerstone cytokine involved in the inflammation and development of psoriasis, ankylosing spondylitis, and psoriatic arthritis.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Amazon.com Inc. said it plans to open a new corporate office in Manchester in 2019 and create more than 1,000 highly-skilled jobs in the UK. As part of the ramp up of its UK investment, Amazon will increase the capacity of its Scotland Development Centre and Cambridge Development Centre. The company's 1,000 new staffers will work on research and development in the UK. Ford will launch its new "Built Ford Proud" U.S. advertising campaign this weekend as the automaker grapples with slowing sales and plans to restructure its operations in order to cut costs. The ad campaign will highlight Ford's 115-year history of manufacturing cars and comes as the automaker intends to replace 75 percent of its U.S. lineup by 2020. The Procter & Gamble Company (PG) reported first-quarter core earnings per share of $1.12, an increase of three percent versus the prior year, as benefits from a lower tax rate due to implementation of the U.S. Tax Act was partially offset by a reduction in operating margin, driven largely by negative...
Follow RTT